Lilly's Olumiant (Baricitinib) is the first Korean JAK inhibitor to acquire atopic dermatitis.

Lilly Korea announced on the 26th that Olumiant received approval from the MFDS to expand its indications to treat secondary or severe atopic dermatitis in adult patients subject to systemic therapy on the 24th. Olumiant has acquired two indication for diseases, following severe active rheumatoid arthritis, which was previously recognized in Korea.

Atopic dermatitis is a chronic inflammatory disease that is typical of itching. This causes scratching, leading to worsening skin inflammation and skin pain. In addition, the majority of patients suffer from itching and accompanying symptoms such as s